Michael Handley Joins PetVivo Holdings, Inc. Board of Directors
https://www.globenewswire.com/news-release/20...ctors.html
MINNEAPOLIS, MN, US, Sept. 22, 2026 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQX: PETV) (the “Company”), together with its subsidiaries PetVivo Animal Health, Inc., Somatrix Technologies, Inc. and PetVivo AI, Inc., an emerging biomedical device company focused on the commercialization of innovative medical devices and therapeutics for companion animals, today announced the appointment of Michael K. Handley to its Board of Directors, effective September 22, 2026.
“We are pleased to welcome Michael Handley to PetVivo’s Board of Directors,” said John Lai, Chief Executive Officer of PetVivo Holdings, Inc. “Michael brings extensive experience in building life sciences companies, raising capital and guiding technologies through development and commercialization. His perspective across biotechnology, pharmaceuticals and medical devices will be valuable as we work to expand adoption of our products, evaluate strategic opportunities and build long-term shareholder value.”
Mr. Handley is a life sciences executive and board director with more than 25 years of experience in the biotechnology, pharmaceutical and medical device industries. He has raised more than $700 million in public and private capital, supported more than 80 global product launches, and led or contributed to transactions with an aggregate value exceeding $4 billion. His experience spans corporate strategy and governance, capital markets, mergers and acquisitions, licensing, clinical development, regulatory affairs and global commercialization.
Mr. Handley most recently served as Chief Executive Officer and a director of Valion Bio, Inc. Previously, he was President, Chief Executive Officer and Chairman of Statera Biopharma, Inc., and held chief executive and director roles at Immune Therapeutics, Corp and Armis Biopharma. He also helped found Vessix Vascular, Inc., where he served as Vice President of Clinical, Quality and Regulatory until its acquisition by Boston Scientific Corporation in 2012.
Mr. Handley graduated cum laude from Colorado State University with a B.S. in Molecular Biology and Physiology. He attended the Executive MBA program at Pepperdine University and completed the Global C-Suite Program at the Wharton School of the University of Pennsylvania.
“I am excited to join PetVivo’s Board and work with John and the leadership team,” said Mr. Handley. “PetVivo’s focus on bringing innovative technologies to veterinary medicine, together with the potential to develop applications in human health, aligns closely with my experience in life sciences development and commercialization. I look forward to helping the Company evaluate growth opportunities, develop strategic relationships and advance its business in ways that support veterinarians, the animals they care for and, over time, potential human healthcare applications, while building long-term shareholder value.”
Mr. Handley fills the vacancy created by Joseph Jasper’s resignation, effective September 22, 2026. The Board thanks Mr. Jasper for his leadership, guidance and contributions during his tenure. Following these changes, the Board continues to consist of six directors.
https://www.globenewswire.com/news-release/20...ctors.html
MINNEAPOLIS, MN, US, Sept. 22, 2026 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQX: PETV) (the “Company”), together with its subsidiaries PetVivo Animal Health, Inc., Somatrix Technologies, Inc. and PetVivo AI, Inc., an emerging biomedical device company focused on the commercialization of innovative medical devices and therapeutics for companion animals, today announced the appointment of Michael K. Handley to its Board of Directors, effective September 22, 2026.
“We are pleased to welcome Michael Handley to PetVivo’s Board of Directors,” said John Lai, Chief Executive Officer of PetVivo Holdings, Inc. “Michael brings extensive experience in building life sciences companies, raising capital and guiding technologies through development and commercialization. His perspective across biotechnology, pharmaceuticals and medical devices will be valuable as we work to expand adoption of our products, evaluate strategic opportunities and build long-term shareholder value.”
Mr. Handley is a life sciences executive and board director with more than 25 years of experience in the biotechnology, pharmaceutical and medical device industries. He has raised more than $700 million in public and private capital, supported more than 80 global product launches, and led or contributed to transactions with an aggregate value exceeding $4 billion. His experience spans corporate strategy and governance, capital markets, mergers and acquisitions, licensing, clinical development, regulatory affairs and global commercialization.
Mr. Handley most recently served as Chief Executive Officer and a director of Valion Bio, Inc. Previously, he was President, Chief Executive Officer and Chairman of Statera Biopharma, Inc., and held chief executive and director roles at Immune Therapeutics, Corp and Armis Biopharma. He also helped found Vessix Vascular, Inc., where he served as Vice President of Clinical, Quality and Regulatory until its acquisition by Boston Scientific Corporation in 2012.
Mr. Handley graduated cum laude from Colorado State University with a B.S. in Molecular Biology and Physiology. He attended the Executive MBA program at Pepperdine University and completed the Global C-Suite Program at the Wharton School of the University of Pennsylvania.
“I am excited to join PetVivo’s Board and work with John and the leadership team,” said Mr. Handley. “PetVivo’s focus on bringing innovative technologies to veterinary medicine, together with the potential to develop applications in human health, aligns closely with my experience in life sciences development and commercialization. I look forward to helping the Company evaluate growth opportunities, develop strategic relationships and advance its business in ways that support veterinarians, the animals they care for and, over time, potential human healthcare applications, while building long-term shareholder value.”
Mr. Handley fills the vacancy created by Joseph Jasper’s resignation, effective September 22, 2026. The Board thanks Mr. Jasper for his leadership, guidance and contributions during his tenure. Following these changes, the Board continues to consist of six directors.
